PARIS--(BUSINESS WIRE)--Jun 11, 2018--Regulatory News:

(FR0011191287 - ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced its upcoming participation in five international scientific conferences in June and July 2018 throughout Europe and the United States.

Pharnext will share the latest scientific and clinical data regarding PXT3003, a drug candidate which is currently being evaluated in an ongoing international pivotal Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A. Pharnext will also illustrate the benefits of its disruptive R&D approach PLEOTHERAPY™ in developing drug combinations, and discuss the Company’s Phase 2 trial of PXT864 for the treatment of Alzheimer’s disease.

The company will attend the following events:

European Academy of Neurology (EAN) congress June 16-18, 2018 in Lisbon, Portugal

Two ePosters (oral communications)

International Congress on Neuromuscular Diseases (ICNMD) July 6-10, 2018 in Vienna, Austria

Two Posters

Innovations and State of the Art In Dementia Research meeting (ISADR) July 16-18, 2081 in Valencia, Spain

Two Oral Communications

Peripheral Nerve Society (PNS) congress July 22-25, 2018 in Baltimore, US

One Oral Communication

Four Posters

Alzheimer's Association International Conference (AAIC) July 22-26, 2018 in Chicago, US

Two Posters

If you are interested in meeting the Pharnext team during either of these events or if you need more information about Pharnext’s participation, please send an email to

About Pharnext Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287). For more information, visit

View source version on

CONTACT: Pharnext

Xavier Paoli, +33 (0)1 41 09 22 30

Chief Commercial Officer


Financial Communication (France)


Stéphane Ruiz, +33 (0)1 56 88 11 15


Investor Relations (U.S.)

Stern Investor Relations, Inc.

Matthew Shinseki, +1 212 362 1200


Investor Relations (Europe)

MC Services AG

Anne Hennecke, +49 211 529252 22


Media Relations (Europe)

Ulysse Communication

Bruno Arabian, +33 (0)1 81 70 96 30


Media Relations (U.S.)


Kate L. Barrette, +1 212 223 0561



SOURCE: Pharnext SA

Copyright Business Wire 2018.

PUB: 06/11/2018 11:25 AM/DISC: 06/11/2018 11:25 AM